Literature DB >> 30353489

A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.

Shonan Sho1,2,3, Colin M Court4,5, Paul Winograd4,5, Paul A Toste4, Joseph R Pisegna6,7, Michael Lewis8, Timothy R Donahue4,9, Oscar J Hines4,9, Howard A Reber4,9, David W Dawson10,11, James S Tomlinson4,5,9.   

Abstract

BACKGROUND: Patients with early-stage pancreatic neuroendocrine tumors (PNETs) may develop metastatic recurrences despite undergoing potentially curative pancreas resections. We sought to identify factors predictive of metastatic recurrences and develop a prognostication strategy to predict recurrence-free survival (RFS) in resected PNETs.
METHODS: Patients with localized PNETs undergoing surgical resection between 1989 and 2015 were identified. Univariate and multivariate analysis were used to identify potential predictors of post-resection metastasis. A score-based prognostication system was devised using the identified factors. The bootstrap model validation methodology was utilized to estimate the external validity of the proposed prognostication strategy.
RESULTS: Of the 140 patients with completely resected early-stage PNETs, overall 5- and 10-year RFS were 84.6% and 67.1%, respectively. The median follow-up was 56 months. Multivariate analysis identified tumor size > 5 cm, Ki-67 index 8-20%, lymph node involvement, and high histologic grade (G3, or Ki-67 > 20%) as independent predictors of post-resection metastatic recurrence. A scoring system based on these factors stratified patients into three prognostic categories with distinct 5-year RFS: 96.9%, 54.8%, and 33.3% (P < 0.0001). The bootstrap model validation methodology projected our proposed prognostication strategy to retain a high predictive accuracy even when applied in an external dataset (validated c-index of 0.81).
CONCLUSIONS: The combination of tumor size, LN status, grade, and Ki-67 was identified as the most highly predictive indicators of metastatic recurrences in resected PNETs. The proposed prognostication strategy may help stratify patients for adjuvant therapies, enhanced surveillance protocols and future clinical trials.

Entities:  

Keywords:  Neoplasm recurrence; Neuroendocrine tumors; Pancreas; Surgical oncology

Mesh:

Substances:

Year:  2018        PMID: 30353489      PMCID: PMC6736531          DOI: 10.1007/s11605-018-4011-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

1.  The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement.

Authors:  Günter Klöppel; Guido Rindi; Aurel Perren; Paul Komminoth; David S Klimstra
Journal:  Virchows Arch       Date:  2010-04-27       Impact factor: 4.064

2.  Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients.

Authors:  Jan Franko; Wentao Feng; Linwah Yip; Elizabeth Genovese; A James Moser
Journal:  J Gastrointest Surg       Date:  2009-12-09       Impact factor: 3.452

3.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

4.  A simplified prognostic system for resected pancreatic neuroendocrine neoplasms.

Authors:  Nikiforos Ballian; Agnes G Loeffler; Victoria Rajamanickam; Peter A Norstedt; Sharon M Weber; Clifford S Cho
Journal:  HPB (Oxford)       Date:  2009-08       Impact factor: 3.647

5.  Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?

Authors:  Cristina R Ferrone; Laura H Tang; James Tomlinson; Mithat Gonen; Steven N Hochwald; Murray F Brennan; David S Klimstra; Peter J Allen
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

6.  Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Authors:  Joshua S Hill; James T McPhee; Theodore P McDade; Zheng Zhou; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

Review 7.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 8.  Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.

Authors:  Mina Jamali; Runjan Chetty
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

9.  Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Authors:  Karl Y Bilimoria; Mark S Talamonti; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

10.  Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients.

Authors:  Karl Y Bilimoria; James S Tomlinson; Ryan P Merkow; Andrew K Stewart; Clifford Y Ko; Mark S Talamonti; David J Bentrem
Journal:  J Gastrointest Surg       Date:  2007-09-11       Impact factor: 3.452

View more
  7 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

Review 3.  Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice.

Authors:  Angela Lamarca; Hamish Clouston; Jorge Barriuso; Mairéad G McNamara; Melissa Frizziero; Was Mansoor; Richard A Hubner; Prakash Manoharan; Sarah O'Dwyer; Juan W Valle
Journal:  J Clin Med       Date:  2019-10-05       Impact factor: 4.241

Review 4.  Surgical Management of Neuroendocrine Tumours of the Pancreas.

Authors:  Regis Souche; Christian Hobeika; Elisabeth Hain; Sebastien Gaujoux
Journal:  J Clin Med       Date:  2020-09-16       Impact factor: 4.241

Review 5.  Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know.

Authors:  Charles de Ponthaud; Fabrice Menegaux; Sébastien Gaujoux
Journal:  Cancers (Basel)       Date:  2021-11-27       Impact factor: 6.639

6.  Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014.

Authors:  Nikolaos A Trikalinos; Benjamin R Tan; Manik Amin; Jingxia Liu; Ramaswamy Govindan; Daniel Morgensztern
Journal:  BMC Endocr Disord       Date:  2020-04-03       Impact factor: 2.763

7.  c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation.

Authors:  Tsung-Ming Chang; Pei-Yi Chu; Wen-Chun Hung; Yan-Shen Shan; Hui-You Lin; Kuo-Wei Huang; Jeffrey S Chang; Li-Tzong Chen; Hui-Jen Tsai
Journal:  Cancer Sci       Date:  2020-11-24       Impact factor: 6.518

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.